U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. About FDA
  3. FDA Organization
  4. Oncology Center of Excellence
  5. Project Catalyst
  1. Oncology Center of Excellence

Project Catalyst

Providing a regulatory platform to connect scientific knowledge, creative insight, and medical professionals to foster early-stage product innovation

Image
Project Catalyst

Advances in science and technology, and an evolving academic environment, have accelerated the growth of start-up companies developing anticancer therapies. With the increasing numbers of small innovative companies emerging from academia, the Oncology Center of Excellence Project Catalyst was developed.

Working primarily with small pharmaceutical companies and academic life science incubators and accelerators, Project Catalyst provides guidance and educational resources that help support informed anticancer therapy development to expedite the availability of directed and novel cancer treatments to the public. 

Accelerator Innovator Discussion (AID) Meetings

Project Catalyst can facilitate “Speed Dating” like interactions with Project Teams at your Academic Accelerators and Life Science Hubs through virtual meetings, allowing investigators to ask questions regarding their drug development plans at an early stage prior to a Pre-IND Meeting. Contact Project Catalyst at OCE-Catalyst@fda.hhs.gov for more information and to coordinate a session.

Oncology Regulatory Expertise and Early Guidance (OREEG)

Project Catalyst’s educational initiative entitled Oncology Regulatory Expertise and Early Guidance (OREEG) is a self-directed platform providing early-stage oncology companies with product-type advice to inform sound product-specific drug development decisions. 

Meetings and Workshops


Project Leaders:

Marc R. Theoret, MD, Deputy Director, Oncology Center of Excellence
Jeff Summers, MD, Associate Director Translational Sciences, Office Oncologic Drugs

Please send your questions and information to Jeffery Summers at:
OCE-Catalyst@fda.hhs.gov

Additional Information: 

FDA Oncology Center of Excellence
CDER Small Business & Industry Assistance (SBIA)

Twitter: #OCECatalyst
Back to Top